Aller au contenu

Publications scientifiques

  • article Lorusso D, Colombo N, Dubot C, Cáceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüş M, Olivera M, Samouëlian V, Castonguay V, Arkhipov A, Li K, Toker S, Tekin C, Tewari KS, Monk BJ

    Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study

    Ann Oncol 36 (1), 2025.

    DOI PUBMED
  • article Tewari KS, Colombo N, Monk BJ, Dubot C, Cáceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüs M, Olivera Hurtado de Mendoza M, Samouëlian V, Castonguay V, Arkhipov A, Tekin C, Li K, Toker S, Keefe SM, Lorusso D

    Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomize…

    JAMA Oncol 10 (2), 2024.

    DOI PUBMED
  • article Choueiri TK, Kuzel TM, Tykodi SS, Verzoni E, Kluger H, Nair S, Perets R, George S, Gurney H, Pachynski RK, Folefac E, Castonguay V, Lee CH, Vaishampayan U, Miller WH, Bhagavatheeswaran P, Wang Y, Gupta S, DeSilva H, Lee CW, Escudier B, Motzer RJ

    Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial

    ESMO Open 9 (12), 2024.

    DOI PUBMED
  • article Graham J, Ahmad AE, Basappa NS, Bernhard JC, Bhindi B, Bossé D, Breau RH, Canil CM, Castonguay V, Finelli A, Heng DYC, Inman BA, Kollmannsberger C, Lalani AA, Lavallée LT, Msaouel P, Prendeville S, Soleimani M, Tanguay S, Wood L, Richard PO

    2024 CUA-KCRNC Expert Report: Management of non-clear cell renal cell carcinoma

    Can Urol Assoc J 18 (11), 2024.

    DOI PUBMED
  • article Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, Castellano D, Fornarini G, Li JR, Mar N, Loriot Y, Duran I, Drakaki A, Narayanan S, Yu X, Gorla S, Homet Moreno B, van der Heijden MS and

    Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

    N Engl J Med 390 (10), 2024.

    DOI PUBMED
  • article Monk BJ, Colombo N, Tewari KS, Dubot C, Caceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüş M, Olivera Hurtado de Mendoza M, Samouëlian V, Castonguay V, Arkhipov A, Tekin C, Li K, Keefe SM, Lorusso D and

    First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826

    J Clin Oncol 41 (36), 2023.

    DOI PUBMED
  • article Monk BJ, Tewari KS, Dubot C, Caceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüş M, Hurtado de Mendoza MO, Samouëlian V, Castonguay V, Arkhipov A, Tekin C, Li K, Martin Nguyen A, Monberg MJ, Colombo N, Lorusso D

    Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826)…

    Lancet Oncol 24 (4), 2023.

    DOI PUBMED
  • article Lalani AA, Kapoor A, Basappa NS, Bhindi B, Bjarnason GA, Bosse D, Breau RH, Canil CM, Cardenas LM, Castonguay V, Chavez-Munoz C, Chu W, Dudani S, Graham J, Heng DYC, Kollmannsberger C, Lattouf JB, Morgan S, Reaume MN, Richard PO, Swaminath A, Tanguay S, Wood LA, Lavallée LT

    Adjuvant therapy for renal cell carcinoma: 2023 Canadian Kidney Cancer Forum consensus statement

    Can Urol Assoc J 17 (5), 2023.

    DOI PUBMED
  • article Colombo N, Dubot C, Lorusso D, Caceres MV, Hasegawa K, Shapira-Frommer R, Tewari KS, Salman P, Hoyos Usta E, Yanez E, Gumus M, Olivera Hurtado de Mendoza M, Samouelian V, Castonguay V, Arkhipov A, Toker S, Li K, Keefe SM, Monk BJ and

    Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

    Obstet Gynecol Surv 77 (1), 2022.

    DOI
  • article Choueiri TK, Kluger H, George S, Tykodi SS, Kuzel TM, Perets R, Nair S, Procopio G, Carducci MA, Castonguay V, Folefac E, Lee CH, Hotte SJ, Miller WH, Saggi SS, Lee CW, Desilva H, Bhagavatheeswaran P, Motzer RJ, Escudier B

    FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy

    J Immunother Cancer 10 (11), 2022.

    DOI PUBMED
  • article Zhang H, Basappa NS, Ghosh S, Joy I, Lalani AKA, Hansen AR, Heng DYC, Castonguay V, Kollmannsberger CK, Winquist E, Wood L, Bjarnason GA, Breau RH, Kapoor A, Graham J

    Real-Word Experience of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis)

    Kidney Cancer 5 (1), 2021.

    DOI
  • article Colombo N, Dubot C, Lorusso D, Caceres MV, Hasegawa K, Shapira-Frommer R, Tewari KS, Salman P, Hoyos Usta E, Yañez E, Olivera Hurtado de Mendoza M, Castonguay V, Arkhipov A, Toker S, Li K, Keefe SM, Monk BJ and

    Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

    N Engl J Med 385 (20), 2021.

    DOI PUBMED